Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AMR PH GL 2007 CL001 Phase 3 A Randomized, Open-Label, Multinational Phase 3 Trial Comparing Amrubicin Versus Topotecan in Patients With Extensive or Limited and Sensitive or Refractory Small Cell Lung Cancer After Failure of First-Line Chemotherapy

NCT00547651 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT00547651
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00547651 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AMR PH GL 2007 CL001 Phase 3 A Randomized, Open-Label, Multinational Phase 3 Trial Comparing Amrubicin Versus Topotecan in Patients With Extensive or Limited and Sensitive or Refractory Small Cell Lung Cancer After Failure of First-Line Chemotherapy
Lead sponsor
Celgene
Phase
Phase 3
Overall status
Completed
Start date
September 1, 2007
Completion date
May 1, 2011
Enrollment
637 (actual)
Sites
140

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer